Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Viral and Symptom Rebound in Untreated COVID-19 Infection

Rinki Deo, Manish C. Choudhary, Carlee Moser, Justin Ritz, Eric S. Daar, David A. Wohl, Alexander L. Greninger, Joseph J. Eron, Judith S. Currier, Michael D. Hughes, Davey M. Smith, Kara W. Chew, Jonathan Z. Li, the ACTIV-2/A5401 Study Team
doi: https://doi.org/10.1101/2022.08.01.22278278
Rinki Deo
1Brigham and Women’s Hospital, Harvard Medical School, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Manish C. Choudhary
1Brigham and Women’s Hospital, Harvard Medical School, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carlee Moser
2Harvard T.H. Chan School of Public Health, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Justin Ritz
2Harvard T.H. Chan School of Public Health, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eric S. Daar
3Lundquist Institute at Harbor-University of California, Los Angeles Medical Center, Torrance, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David A. Wohl
4University of North Carolina, Chapel Hill, NC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alexander L. Greninger
5University of Washington Medical Center, Seattle, WA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joseph J. Eron
4University of North Carolina, Chapel Hill, NC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Judith S. Currier
6David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael D. Hughes
2Harvard T.H. Chan School of Public Health, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Davey M. Smith
7University of California, San Diego, San Diego, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kara W. Chew
6David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jonathan Z. Li
1Brigham and Women’s Hospital, Harvard Medical School, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: jli@bwh.harvard.edu
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Summary

Background There are reports of viral RNA and symptom rebound in people with COVID-19 treated with nirmatrelvir/ritonavir. Since the natural course of viral and symptom trajectories of COVID-19 has not been well described, we evaluated the incidence of viral and symptom rebound in untreated outpatients with mild-moderate COVID-19.

Methods The study population included 568 participants enrolled in the ACTIV-2/A5401 platform trial who received placebo. Anterior nasal swabs were collected for SARS-CoV-2 RNA testing on days 0-14, 21 and 28. Participants recorded the severity of 13 targeted symptoms daily from day 0 to 28. Viral rebound was defined as ≥0.5 log10 viral RNA copies/mL increase and symptom rebound was defined as a 4-point total symptom score increase from baseline. Baseline was defined as study day 4 (primary analysis) or 8 days from symptom onset (secondary analysis).

Findings In both the primary and secondary analyses, 12% of participants had viral rebound. Viral rebounders were older than non-rebounders (median 54 vs 47 years, P=0.04). Symptom rebound occurred in 27% of participants after initial symptom improvement and in 10% of participants after initial symptom resolution. The combination of high-level viral rebound to ≥5.0 log10 RNA copies/mL and symptom rebound after initial improvement was observed in 1-2% of participants.

Interpretation Viral RNA rebound or symptom relapse in the absence of antiviral treatment is common, but the combination of high-level viral and symptom rebound is rare.

Funding This study was supported by the National Institute of Allergy and Infectious Diseases; ACTIV-2/A5401 ClinicalTrials.gov number NCT04518410.

Competing Interest Statement

KWC has received research funding to the institution from Merck Sharp & Dohme and is a consultant for Pardes Bioscences. ESD has consulted for Gilead, Merck and ViiV and received research support from Gilead and ViiV. JZL has consulted for Abbvie and received research funding from Merck. JSC has consulted for Merck & Company. ALG reports contract testing from Abbott, Cepheid, Novavax, Pfizer, Janssen and Hologic and research support from Gilead and Merck, outside of the described work. JJE has consulted for GSK, and Merck. DAW has consulted for Gilead and ViiV and received research support from Gilead, ViiV, and Lilly.

Clinical Trial

NCT04518410

Funding Statement

This work was supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under Award Number UM1 AI106701, UM1AI068634 (MDH), UM1AI068636 (JSC) and UM1AI106701 (GA). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The protocol was approved by a central institutional review board (IRB), Advarra (Pro00045266), with additional local IRB review and approval as required by participating sites. All participants provided written informed consent.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Data are available under restricted access due to ethical restrictions. Access can be requested by submitting a data request at https://submit.mis.s-3.net/ and will require the written agreement of the AIDS Clinical Trials Group (ACTG) and the manufacturer of the investigational product. Requests will be addressed as per ACTG standard operating procedures. Completion of an ACTG Data Use Agreement may be required. All analyses were performed using code available in standard software packages. No new code was developed for this manuscript.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted August 02, 2022.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Viral and Symptom Rebound in Untreated COVID-19 Infection
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Viral and Symptom Rebound in Untreated COVID-19 Infection
Rinki Deo, Manish C. Choudhary, Carlee Moser, Justin Ritz, Eric S. Daar, David A. Wohl, Alexander L. Greninger, Joseph J. Eron, Judith S. Currier, Michael D. Hughes, Davey M. Smith, Kara W. Chew, Jonathan Z. Li, the ACTIV-2/A5401 Study Team
medRxiv 2022.08.01.22278278; doi: https://doi.org/10.1101/2022.08.01.22278278
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Viral and Symptom Rebound in Untreated COVID-19 Infection
Rinki Deo, Manish C. Choudhary, Carlee Moser, Justin Ritz, Eric S. Daar, David A. Wohl, Alexander L. Greninger, Joseph J. Eron, Judith S. Currier, Michael D. Hughes, Davey M. Smith, Kara W. Chew, Jonathan Z. Li, the ACTIV-2/A5401 Study Team
medRxiv 2022.08.01.22278278; doi: https://doi.org/10.1101/2022.08.01.22278278

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (271)
  • Allergy and Immunology (557)
  • Anesthesia (135)
  • Cardiovascular Medicine (1769)
  • Dentistry and Oral Medicine (238)
  • Dermatology (173)
  • Emergency Medicine (316)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (662)
  • Epidemiology (10812)
  • Forensic Medicine (8)
  • Gastroenterology (594)
  • Genetic and Genomic Medicine (2960)
  • Geriatric Medicine (288)
  • Health Economics (534)
  • Health Informatics (1933)
  • Health Policy (836)
  • Health Systems and Quality Improvement (745)
  • Hematology (293)
  • HIV/AIDS (633)
  • Infectious Diseases (except HIV/AIDS) (12525)
  • Intensive Care and Critical Care Medicine (696)
  • Medical Education (300)
  • Medical Ethics (87)
  • Nephrology (324)
  • Neurology (2808)
  • Nursing (152)
  • Nutrition (433)
  • Obstetrics and Gynecology (559)
  • Occupational and Environmental Health (597)
  • Oncology (1473)
  • Ophthalmology (444)
  • Orthopedics (172)
  • Otolaryngology (257)
  • Pain Medicine (190)
  • Palliative Medicine (56)
  • Pathology (381)
  • Pediatrics (868)
  • Pharmacology and Therapeutics (367)
  • Primary Care Research (338)
  • Psychiatry and Clinical Psychology (2646)
  • Public and Global Health (5383)
  • Radiology and Imaging (1016)
  • Rehabilitation Medicine and Physical Therapy (597)
  • Respiratory Medicine (727)
  • Rheumatology (330)
  • Sexual and Reproductive Health (290)
  • Sports Medicine (279)
  • Surgery (327)
  • Toxicology (48)
  • Transplantation (150)
  • Urology (126)